PT  - JOURNAL ARTICLE
AU  - Zinszer, K
AU  - McKinnon, B
AU  - Bourque, N
AU  - Zahreddine, M
AU  - Charland, K
AU  - Papenburg, J
AU  - Fortin, G
AU  - Hamelin, ME
AU  - Saucier, A
AU  - Apostolatos, A
AU  - Pierce, L
AU  - Savard-Lamothe, A
AU  - Carbonneau, Julie
AU  - Conrod, P
AU  - Haley, N
AU  - Laurin, I
AU  - Boivin, G
AU  - De Serres, G
AU  - Quach, C
TI  - Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: Protocol for a cohort study in Montreal, Canada
AID  - 10.1101/2021.04.14.21255499
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.14.21255499
4099  - http://medrxiv.org/content/early/2021/04/16/2021.04.14.21255499.short
4100  - http://medrxiv.org/content/early/2021/04/16/2021.04.14.21255499.full
AB  - Background Further evidence is needed to understand the contribution of schools and daycares to the spread of COVID-19 in the context of diverse transmission dynamics and continually evolving public health interventions. The Enfants et COVID-19: Étude de séroprévalence (EnCORE) study will estimate the seroprevalence and seroconversion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among school and daycare children and personnel. In addition, the study will examine associations between seroprevalence and socio-demographic characteristics and reported COVID-19 symptoms and tests, and investigates changes in health, lifestyle and well-being outcomes.Methods This study includes children and personnel from 62 schools and daycares in four neighbourhoods in Montreal, Canada. All children age 2-17 years attending one of the participating schools or daycares and their parents are invited to participate, as well as a sample of personnel members. Participants respond to brief questionnaires and provide blood samples, collected via dried blood spot (DBS), at baseline (October 2020-March 2021) and follow-up (May-June 2021). Questionnaires include socio-demographic and household characteristics, reported COVID-19 symptoms and tests, potential COVID-19 risk factors and prevention efforts, and health and lifestyle information. Logistic regression using generalized estimating equations will be used to estimate seroprevalence and seroconversion, accounting for school-level clustering.Discussion The results of the EnCORE study will contribute to our knowledge about SARS-CoV-2 transmission in schools and daycares, which is critical for decisions regarding school attendance and the management of school outbreaks through the remainder of this school year and beyond.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by Public Health Agency of Canada through the COVID-19 Immunity Task Force. The funders had no role in the design of the study, data collection, analysis, interpretation of data, and writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the research ethics boards of the Université de Montréal (CERSES) and the Centre Hospitalier Universitaire Sainte-Justine. The study was also reviewed and approved by three of the participating school boards: Centre de services scolaire de Montreal, Centre de services scolaire Marguerite-Bourgeoys, and the English Montreal School Board and approved by two other participating school boards: Lester B. Pearson School Board and Centre de services scolaire de la Pointe-de-l’île. Written (electronically) informed consent is obtained from parents or legal guardians of participating children, while written assent (electronically) is obtained from participating children. Participating daycare and school personnel, as well as household members of seropositive children, also provide informed written consent (electronically).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study will become publicly available upon completion of the study and will be available from the corresponding author on reasonable request.DBSDried blood spotELISAEnzyme-linked immunosorbent assayEnCOREEnfants et COVID-19: Étude de séroprévalenceGAD-7Generalized Anxiety Disorder-7IgGImmunoglobulin GIMSEIndice de milieu socio-économique (Socio-economic index)MNMicro neutralizationODOptic densityPHQ-9Patient Health Questionnaire-9PCRPolymerase chain reactionPRSPProgramme Régionale de Santé Publique (regional public health program)RBDReceptor-binding domainSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SDQStrengths and Difficulties Questionnaire